Chikashi Ishioka

Summary

Affiliation: Tohoku University
Country: Japan

Publications

  1. pmc Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast
    C Ishioka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba ku, Sendai, Japan
    Proc Natl Acad Sci U S A 94:2449-53. 1997
  2. ncbi request reprint Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells
    C Ishioka
    Department of Clinical Oncology, Tohoku University, Sendai, Japan
    Biochem Biophys Res Commun 232:54-60. 1997
  3. doi request reprint Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer
    Hiroshi Soeda
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aobaku, Sendai, 980 8575, Japan
    Int J Clin Oncol 18:670-7. 2013
  4. ncbi request reprint [A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy]
    Yuichi Kakudo
    Dept of Clinical Oncology, Institute of Development, Aging and Cancer and Tohoku University Hospital, Tohoku University
    Gan To Kagaku Ryoho 33:969-72. 2006
  5. ncbi request reprint Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma
    Chieko Kudo
    Department of Clinical Oncology, Faculty of Medicine, Akita University, Hondo1 1 1, Akita, Japan
    Anticancer Res 31:3719-26. 2011
  6. doi request reprint Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof
    Hiroyuki Yamakoshi
    Graduate School of Pharmaceutical Sciences, Tohoku University, 6 3 Aobayama, Sendai, Japan
    Bioorg Med Chem 18:1083-92. 2010
  7. ncbi request reprint Identification and evaluation of 55 genetic variations in the BRCA1 and the BRCA2 genes of patients from 50 Japanese breast cancer families
    Masanori Kawahara
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai 980 8575, Japan
    J Hum Genet 49:391-5. 2004
  8. doi request reprint Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus
    Hisanori Ariga
    Department of Radiation Oncology, Tohoku University School of Medicine, Sendai, Japan
    Int J Radiat Oncol Biol Phys 75:348-56. 2009
  9. ncbi request reprint Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library
    Kazuko Shiraishi
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980 8575, Japan
    J Biol Chem 279:348-55. 2004
  10. doi request reprint Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis
    Atsuko Sato
    Department of Clinical Oncology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan
    Cancer Sci 102:1045-51. 2011

Detail Information

Publications75

  1. pmc Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast
    C Ishioka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba ku, Sendai, Japan
    Proc Natl Acad Sci U S A 94:2449-53. 1997
    ..This approach offers a rapid and reliable method for genetic diagnosis in individuals at high risk for germ-line mutations in cancer susceptibility genes...
  2. ncbi request reprint Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells
    C Ishioka
    Department of Clinical Oncology, Tohoku University, Sendai, Japan
    Biochem Biophys Res Commun 232:54-60. 1997
    ....
  3. doi request reprint Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer
    Hiroshi Soeda
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aobaku, Sendai, 980 8575, Japan
    Int J Clin Oncol 18:670-7. 2013
    ..Among activating mutations downstream of EGFR, the KRAS mutation, which is present in 30-45 % of CRC patients, has shown to be a predictive biomarker of resistance to anti-EGFR antibody therapy based on Caucasian studies...
  4. ncbi request reprint [A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy]
    Yuichi Kakudo
    Dept of Clinical Oncology, Institute of Development, Aging and Cancer and Tohoku University Hospital, Tohoku University
    Gan To Kagaku Ryoho 33:969-72. 2006
    ..Weekly paclitaxel therapy was reasonably safe as reported in other reports and considered to be a promising regimen for malignant melanoma of the esophagus...
  5. ncbi request reprint Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma
    Chieko Kudo
    Department of Clinical Oncology, Faculty of Medicine, Akita University, Hondo1 1 1, Akita, Japan
    Anticancer Res 31:3719-26. 2011
    ..Curcumin can regulate these molecules, but its low bioavailability prevents its clinical application...
  6. doi request reprint Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof
    Hiroyuki Yamakoshi
    Graduate School of Pharmaceutical Sciences, Tohoku University, 6 3 Aobayama, Sendai, Japan
    Bioorg Med Chem 18:1083-92. 2010
    ....
  7. ncbi request reprint Identification and evaluation of 55 genetic variations in the BRCA1 and the BRCA2 genes of patients from 50 Japanese breast cancer families
    Masanori Kawahara
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai 980 8575, Japan
    J Hum Genet 49:391-5. 2004
    ..The pathogenic significance of these coding SNPs (cSNPs) remains to be clarified. The SNP information from this study will be useful in the future genetic testing of both BRCA1 and BRCA2 genes in the Japanese population...
  8. doi request reprint Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus
    Hisanori Ariga
    Department of Radiation Oncology, Tohoku University School of Medicine, Sendai, Japan
    Int J Radiat Oncol Biol Phys 75:348-56. 2009
    ....
  9. ncbi request reprint Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library
    Kazuko Shiraishi
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980 8575, Japan
    J Biol Chem 279:348-55. 2004
    ....
  10. doi request reprint Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis
    Atsuko Sato
    Department of Clinical Oncology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan
    Cancer Sci 102:1045-51. 2011
    ..The enhanced potency of GO-Y030 may make it more useful than curcumin, which suffers from low bioavailability. GO-Y030 is a good lead compound for the development of useful compounds for practical cancer chemotherapy...
  11. ncbi request reprint Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation
    Takashi Yoshioka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai 980 8575, Japan
    Int J Clin Oncol 11:454-60. 2006
    ..We conducted a dose-escalation study of docetaxel and nedaplatin as second line-chemotherapy after definitive chemoradiation in patients with relapsed or refractory squamous cell carcinoma of the esophagus after chemoradiation...
  12. pmc The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence
    Ichiyo Shibahara
    Department of Neurosurgery, Tohoku University School of Medicine, Sendai, Japan
    Neuro Oncol 15:1151-9. 2013
    ..In particular, we examined whether there was a correlation between the expression of CD133 and glioblastoma recurrence...
  13. pmc Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
    Takanori Ishida
    Department of Surgical Oncology, Tohoku University School of Medicine, 1 1 Seiryo machi, Aoba ku, Sendai, 980 8574, Japan
    Cancer Chemother Pharmacol 64:361-9. 2009
    ..The purpose of this study was to investigate the activity of capecitabine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer resistant to both anthracyclines and taxanes...
  14. ncbi request reprint CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer
    Xiaofei Zhang
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1, Seiryo machi, Aobaku, Sendai, 980 8575, Japan
    Int J Clin Oncol 21:1091-1101. 2016
    ..However, the relationship between the effect of standard chemotherapy, including cytotoxic drugs and anti-epidermal growth factor receptor (EGFR) antibodies, and CIMP status has not been elucidated...
  15. pmc Overexpression of DRAM enhances p53-dependent apoptosis
    Masahiro Takahashi
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai, Japan
    Cancer Med 2:1-10. 2013
    ..Here, we show that DRAM is an important gene for the enhancement of p53-dependent apoptosis. Additional analysis of the mechanism of super p53-dependent apoptosis may lead to the identification of novel drug targets for cancer therapy...
  16. ncbi request reprint [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer]
    Natsuko Chiba
    Dept of Clinical Oncology, Institute of Development, Aging and Cancer and Tohoku University Hospital, Tohoku University
    Gan To Kagaku Ryoho 32:991-5. 2005
    ..These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval...
  17. doi request reprint Aberrant splicing caused by a MLH1 splice donor site mutation found in a young Japanese patient with Lynch syndrome
    Masanobu Takahashi
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, and Tohoku University Hospital, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai, Japan
    Fam Cancer 11:559-64. 2012
    ..Our data accumulate more information on the genotype-phenotype relationships in patients with Lynch syndrome...
  18. ncbi request reprint Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancer
    Kazunori Otsuka
    Department of Clinical Oncology, Graduate School of Medicine, Akita University, Akita, Japan
    Anticancer Res 33:625-9. 2013
    ..Changes in the number of CTCs may be a good predictive biomarker. Problems with this method are yet to be resolved, including the detection rate and the stability of the sample source for subsequent molecular analysis...
  19. ncbi request reprint Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays
    Masanobu Takahashi
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University Hospital, Tohoku University, Sendai, Japan
    Cancer Res 67:4595-604. 2007
    ..Integrated functional evaluations contribute to a better prediction of the cancer risk in individuals or families carrying MLH1 variants and provide insights into the function-structure relationships in MLH1...
  20. ncbi request reprint The screening of the second-site suppressor mutations of the common p53 mutants
    Kazunori Otsuka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, and Tohoku University Hospital, Tohoku University, Sendai, Japan
    Int J Cancer 121:559-66. 2007
    ..The intermolecular mechanism may lead to novel strategies for restoring inactivated p53 function and tumor suppression in cancer treatment...
  21. pmc Induction of apoptosis by cytoplasmically localized wild-type p53 and the S121F mutant super p53
    Katsuhiro Yasuda
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi 980 8575, Japan
    Oncol Lett 3:978-982. 2012
    ..These results underscore the existence of transactivation-independent apoptosis and cytoplasmic function of p53...
  22. ncbi request reprint OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer
    Masanobu Takahashi
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai, Miyagi, 980 8575, Japan
    Breast Cancer . 2016
    ..In the present study, we aimed to elucidate whether any genetic mutations in OLA1 are detected among patients with suspected HBOC without BRCA1 or BRCA2 mutations...
  23. ncbi request reprint Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer
    Hisatsugu Ohori
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980 8575, Japan
    Mol Cancer Ther 5:2563-71. 2006
    ..They also exhibited no toxicities in vivo that they may provide effective alternative therapies for the prevention and treatment of some human cancers...
  24. pmc Suppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87
    Sadayuki Kawai
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba ku, Sendai 980 8575, Japan
    Oncol Rep 29:13-20. 2013
    ..Our results suggest that knockdown of FUT1 downregulates HER2 signaling via EGFR downregulation. FUT1 may serve as a new molecular target for HER2-overexpressing human cancers with activated EGFR signaling...
  25. doi request reprint The BRCA1/BARD1-interacting protein OLA1 functions in centrosome regulation
    Ayako Matsuzawa
    Department of Molecular Immunology, Institute of Development, Aging, and Cancer IDAC, Tohoku University, 4 1 Seiryomachi Aoba ku, Sendai 980 8575, Japan
    Mol Cell 53:101-14. 2014
    ..BRCA1 variant I42V also abrogated the binding of BRCA1 to OLA1. These findings suggest that OLA1 plays an important role in centrosome regulation together with BRCA1. ..
  26. doi request reprint Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients
    Shunsuke Kato
    Institute of Development, Department of Clinical Oncology, Aging and Cancer, Tohoku University, Sendai, Japan
    Oncology 83:101-7. 2012
    ..We conducted a randomized phase II trial of modified leucovorin, fluorouracil and irinotecan (mFOLFIRI) + bevacizumab and sequential IRIS + bevacizumab as first- or second-line therapies...
  27. ncbi request reprint AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report
    Natsuko Chiba
    Department of Clinical Oncology, Institute of Development, Aging and Cancer IDAC, Tohoku University Hospital, Tohoku University, Sendai, Japan
    Anticancer Res 25:2965-8. 2005
    ..This is the first report, to our knowledge, of effective chemotherapy for liver metastases from an AFP-producing hepatoid adenocarcinoma of the esophagus...
  28. pmc Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo
    Chieko Kudo
    Dept Clinical Oncology, Institute of Development, Aging, and Cancer, Tohoku University, Seiryo cho 4 1, Aoba ku, Sendai, Japan
    BMC Pharmacol 11:4. 2011
    ..A synthesized curcumin analog, 1,5-diaryl-3-oxo-1,4-pentadiene such as GO-Y030, has the improved anti-tumor potential in vitro as well as in mouse model of colorectal carcinogenesis...
  29. doi request reprint Comparison of cisplatin and 5-fluorouracil chemotherapy protocols combined with concurrent radiotherapy for esophageal cancer
    Toru Sakayauchi
    Department of Radiation Oncology, Tohoku University School of Medicine, Sendai, 980 8574, Japan
    Jpn J Radiol 27:131-7. 2009
    ..This study was performed to identify the differences in toxicity and completion rates of various chemotherapy protocols with that goal in mind...
  30. ncbi request reprint Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo
    Hiroyuki Shibata
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Cancer Sci 100:956-60. 2009
    ..It was demonstrated that the number of beta-catenin-positive adenoma cells in Apc(580D/+) mice fed GO-Y030 was reduced...
  31. pmc Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80
    Leizhen Wei
    Department of Clinical Oncology, Tohoku University, 4 1 Seiryomachi Aoba ku, Sendai 980 8575, Japan
    Mol Cell Biol 28:7380-93. 2008
    ..A P142H mutant failed to associate with Ku80 and restore resistance to irradiation in BRCA1-deficient cells. These might provide a molecular basis of the involvement of BRCA1 in the NHEJ pathway of the DSB repair process...
  32. ncbi request reprint Phase II intermittent (or stop and go) l-OHP administration of first-line bevacizumab (BV) plus mFOLFOX6 or CapeOX therapies in Japanese patients with mCRC: The interim report of T-CORE0901
    Makio Gamoh
    Osaki Citizen Hospital, Osaki, Japan Tohoku University, Sendai, Japan South Miyagi Medical Center, Ohgawara Machi, Japan Miyagi Cancer Center, Sendai, Japan Yamagata University, Yamagata, Japan
    J Clin Oncol 30:664. 2012
    ..The primary endpoint is progression free survival (PFS) and secondary endpoints are tumor response (RR), overall survival (OS), time to treatment failure (TTF) and frequency of neurotoxicity...
  33. doi request reprint Contribution of autophagic cell death to p53-dependent cell death in human glioblastoma cell line SF126
    Yasuhiro Sakamoto
    Department of Clinical Oncology, Research Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Cancer Sci 102:799-807. 2011
    ....
  34. ncbi request reprint A novel germline mutation of the LKB1 gene in a patient with Peutz-Jeghers syndrome with early-onset gastric cancer
    Masanobu Takahashi
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, and Tohoku University Hospital, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai, 980 8575, Japan
    J Gastroenterol 39:1210-4. 2004
    ....
  35. doi request reprint Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer
    Gou Watanabe
    Division of Surgical Oncology, Tohoku University School of Medicine Department of Clinical Oncology, Research Institute of Development, Aging and Cancer, Tohoku University Department of Pathology, Tohoku University Hospital, Sendai Department of Breast Cancer Surgery, Ishinomaki Red Cross Hospital, Miyagi Center for Kampo Medicine, Nerima General Hospital Division of medical oncology, Juntendo University Hospital, Tokyo, Japan
    Am J Surg Pathol 39:1026-34. 2015
    ..Stratification with p53 mt-like IHC identified patients with a poorer prognosis. In conclusion, we identified reliable IHC conditions to predict the TP53 status of breast cancer patients. ..
  36. ncbi request reprint [The state of the art of hereditary cancer studies]
    Chikashi Ishioka
    Dept of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Gan To Kagaku Ryoho 32:962-6. 2005
    ..In this paper, we have outlined the state of the art of studies on hereditary cancer syndrome, focusing on familial breast cancer and hereditary non-polyposis colorectal cancer...
  37. ncbi request reprint The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library
    Tomohiro Kawaguchi
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, and Tohoku University Hospital, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai 980 8575, Japan
    Oncogene 24:6976-81. 2005
    ....
  38. doi request reprint Prediction of breast cancer prognosis by gene expression profile of TP53 status
    Shin Takahashi
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1, Seiryo machi, Aobaku, Sendai, 980 8575, Japan
    Cancer Sci 99:324-32. 2008
    ..Gallen criteria, and high risk in National Cancer Institute (NCI) criteria (log rank, P < 0.0001). TP53 signature is a reliable and independent predictor of the outcome of disease in operated breast cancer...
  39. doi request reprint alphaB-crystallin: a novel p53-target gene required for p53-dependent apoptosis
    Gou Watanabe
    Department of Clinical Oncology, Research Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Cancer Sci 100:2368-75. 2009
    ..This is the first report associating p53 directly with a heat shock protein through trans-activation and physical interaction...
  40. ncbi request reprint [Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody]
    Hideki Shimodaira
    Institute of Development, Aging and Cancer, Tohoku University, Aoba ku, Sendai, Japan
    Gan To Kagaku Ryoho 37:795-8. 2010
    ..Continued research on the immunotherapeutic mechanisms of monoclonal antibodies will improve the efficacy of antibody-based targeted therapy for cancer...
  41. ncbi request reprint Reversibility of the thia-Michael reaction of cytotoxic C5-curcuminoid and structure-activity relationship of bis-thiol-adducts thereof
    Aki Kohyama
    Graduate School of Pharmaceutical Sciences, Tohoku University, 6 3 Aza Aoba, Aramaki, Aoba ku, Sendai 980 8578, Japan
    Org Biomol Chem 14:10683-10687. 2016
    ..These results imply that C5-curcuminoids elicit cytotoxicity by covalently interacting with various biothiols via a reversible thia-Michael reaction...
  42. doi request reprint Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease
    Akihiro Kobayashi
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan
    Intern Med 55:629-34. 2016
    ..However, whether such treatments are effective in patients with VHL disease remains to be elucidated. We herein report a Japanese patient with VHL disease who was successfully treated with sunitinib for approximately 5 years...
  43. ncbi request reprint A Curcumin Analog, GO-Y078, Effectively Inhibits Angiogenesis through Actin Disorganization
    Shunsuke Sugiyama
    Department of Clinical Oncology, Graduate School of Medicine, Akita University, Akita, Japan
    Anticancer Agents Med Chem 16:633-47. 2016
    ..Curcumin can associate with many proteins, and it reportedly inhibits tumor angiogenesis...
  44. pmc Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis
    Shunsuke Kato
    Department of Clinical Oncology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai 980 8575, Japan
    Proc Natl Acad Sci U S A 100:8424-9. 2003
    ..This high-resolution mutation analysis allows evaluation of previous predictions and hypotheses through interrelation of function, structure and mutation...
  45. doi request reprint Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors
    Ken Saijo
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Cancer Sci 103:1994-2001. 2012
    ..In future, optimizing the potency of FK228 and its analogs against PI3K may contribute to the development of novel HDAC/PI3K dual inhibitors for cancer treatment...
  46. doi request reprint IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas
    Ichiyo Shibahara
    Department of Neurosurgery, Tohoku University School of Medicine, 1 1 Seiryo machi, Aoba ku, Sendai, 980 8575, Japan
    Int J Clin Oncol 17:551-61. 2012
    ..However, detailed subgroup analysis of grade III glioma is limited. To address this, we investigated molecular and prognostic features of grade III glioma with and without IDH1/2 mutation...
  47. doi request reprint BRCA1 contributes to transcription-coupled repair of DNA damage through polyubiquitination and degradation of Cockayne syndrome B protein
    Leizhen Wei
    Department of Molecular Immunology, Tohoku University, Sendai
    Cancer Sci 102:1840-7. 2011
    ....
  48. ncbi request reprint O-[18F]fluoromethyl-L-tyrosine is a potential tracer for monitoring tumour response to chemotherapy using PET: an initial comparative in vivo study with deoxyglucose and thymidine
    Gengo Yamaura
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aoba Ward, Sendai 980 8575, Japan
    Eur J Nucl Med Mol Imaging 33:1134-9. 2006
    ..To compare the utility of a new artificial amino acid, O-[18F]fluoromethyl-L-tyrosine ([18F]FMT), for monitoring cancer chemotherapy with deoxyglucose and thymidine...
  49. doi request reprint Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer
    Masahiro Inoue
    Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4 1 Seiryo machi, Aobaku, Sendai, 980 8575, Japan
    Int J Clin Oncol 20:1147-55. 2015
    ....
  50. pmc High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H
    Hiroo Imai
    Department of Clinical Oncology, IDAC, Tohoku University, Sendai, Miyagi 980 8575, Japan
    Oncol Rep 31:1043-50. 2014
    ..ID1 is a synthetic sick/lethal gene that interacts with R175H and is considered to be a novel molecular target for cancer therapy in R175H-expressing cells...
  51. ncbi request reprint Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s
    Yuichi Kakudo
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, and Tohoku University Hospital, Tohoku University, Sendai, Japan
    Cancer Res 65:2108-14. 2005
    ..These results suggested that transactivation-dependent apoptosis does not always play a major role in p53-dependent apoptosis, indirectly supporting the importance role of the transactivation-independent mechanism...
  52. pmc Upper arm central venous port implantation: a 6-year single institutional retrospective analysis and pictorial essay of procedures for insertion
    Masatoshi Shiono
    Department of Clinical Oncology, Tohoku University Hospital, Tohoku University, Aoba ku, Sendai, Japan
    PLoS ONE 9:e91335. 2014
    ..Recently, upper arm implantation has become the first choice as a safe and comfortable method in our unit. Here we report our experience and discuss the procedure and its potential advantages...
  53. doi request reprint Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801)
    Hiroshi Soeda
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Oncology 87:7-20. 2014
    ..This prospective study investigated the relationship between the mutation status of EGFR-related genes including KRAS and the response rate (RR) to cetuximab plus irinotecan therapy in Japanese mCRC patients...
  54. ncbi request reprint Current situation regarding central venous port implantation procedures and complications: a questionnaire-based survey of 11,693 implantations in Japan
    Masatoshi Shiono
    Department of Medical Oncology, Tohoku University Hospital, Tohoku University, Seiryo machi 1 1, Aoba ku, Sendai, 980 8574, Japan
    Int J Clin Oncol 21:1172-1182. 2016
    ..We conducted a nationwide questionnaire-based survey to understand the current situation regarding central venous port implantation in order to identify the ideal procedure...
  55. pmc Functional Complementation Assay for 47 MUTYH Variants in a MutY-Disrupted Escherichia coli Strain
    Keigo Komine
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba ku, Sendai, Japan
    Hum Mutat 36:704-11. 2015
    ..These data will be useful for evaluating the functional consequences of missense MUTYH variants detected in patients with suspected MAP. ..
  56. ncbi request reprint [TP53 mutations and molecular epidemiology]
    Kazunori Otsuka
    Dept of Clinical Oncology, Tohoku University Hospital, Sendai, Japan
    Gan To Kagaku Ryoho 34:683-9. 2007
    ....
  57. pmc Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors
    Ken Saijo
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Cancer Sci 106:208-15. 2015
    ..These results prove our concept that a series of FK228 analogs are HDAC/PI3K dual inhibitors. These findings should help in the development of FK228 analogs as novel HDAC/PI3K dual inhibitors. ..
  58. ncbi request reprint [Infusion reaction and anaphylaxis]
    Kozue Yoshida
    Dept of Clinical Oncology, Tohoku University Hospital, Japan
    Gan To Kagaku Ryoho 38:1753-7. 2011
    ..An acute severe allergic reaction is called anaphylaxis, and is often fatal unless treated appropriately. In this review, we describe the prevention of hypersensitivity reactions and their treatment based on our clinical experience...
  59. ncbi request reprint [Familial breast cancer genes]
    Natsuko Chiba
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University
    Nihon Rinsho 65:601-5. 2007
  60. ncbi request reprint [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer]
    Hiroshi Soeda
    Institute of Development, Aging and Cancer, Tohoku University, Japan
    Gan To Kagaku Ryoho 38:1079-83. 2011
    ..Additional analysis of BRAF, PIK3CA, PTEN and FcqR genes in KRAS wild-type patients could narrow down the selection of patients who are most likely to benefit from anti-EGFR antibody therapy...
  61. pmc DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer
    Kota Ouchi
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Cancer Sci 106:1722-9. 2015
    ..In conclusion, we found that the genome-wide DNA methylation status is a powerful epigenetic predictor of anti-EGFR treatment in patients with KRAS wild-type metastatic colorectal cancer (UMIN000005490). ..
  62. ncbi request reprint Analysis of the human APC mutation spectrum in a saccharomyces cerevisiae strain with a mismatch repair defect
    Kazunori Otsuka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Int J Cancer 103:624-30. 2003
    ..We therefore consider that the differences in the spectra of RER and non-RER tumors are attributable at least in part to the MMR system of the host cells...
  63. pmc Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma
    Takahiro Mori
    Tohoku Community Cancer Services Program, Tohoku University Graduate School of Medicine, Sendai, Japan
    Cancer Sci 106:1118-29. 2015
    ..Taken together, BAP1 is likely to function as a tumor suppressor in at least a part of ESCC...
  64. ncbi request reprint [A multicenter trial of regional medical cooperation for cancer chemotherapy after the great East Japan earthquake]
    Shoko Akiyama
    Dept of Clinical Oncology, Tohoku University Hospital, Japan
    Gan To Kagaku Ryoho 40:343-8. 2013
    ..Based on the trial, we found it important in disasters to establish regional cooperation and solid communication systems, and to promote patient education...
  65. ncbi request reprint Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying protein-truncating mutations in the BRCA1and BRCA2genes in familial breast cancer
    Masato Sakayori
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai 980 8575, Japan
    J Hum Genet 48:130-7. 2003
    ....
  66. ncbi request reprint [Treatment of bone metastasis - focusing on drug treatment]
    Chikashi Ishioka
    Dept of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Miyagi, Japan
    Gan To Kagaku Ryoho 39:1169-73. 2012
    ..It is necessary to arrive at a consensus the application of different modalities and selection of drugs in the treatment of bone metastasis...
  67. ncbi request reprint [Breast cancer and molecular markers]
    Chikashi Ishioka
    Dept of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan
    Gan To Kagaku Ryoho 35:1261-8. 2008
    ..In the revised guideline, gene expression profiling assays are topics in six newly added categories. In this review, the key guideline recommendations and two innovative gene expression profiling assays have been summarized...
  68. ncbi request reprint [Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment]
    Hideki Shimodaira
    Institute of Development, Aging and Cancer, Tohoku University, Tohoku University Hospital, Aoba ku, Sendai, Japan
    Gan To Kagaku Ryoho 36:1063-6. 2009
    ..Further studies must integrate these markers into clinical decisions to use or not use anti-EGFR antibodies...
  69. pmc Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells
    Yuki Yoshino
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Seiryo machi 4 1, Aoba ku, Sendai 980 8575, Japan
    Sci Rep 5:13249. 2015
    ....
  70. doi request reprint Transgenic expression of the N525S-tuberin variant in Tsc2 mutant (Eker) rats causes dominant embryonic lethality
    Masatoshi Shiono
    1 Department of Clinical Oncology, Tohoku University Hospital, Tohoku University, 1 1 Seiryo machi, Aoba ku, Sendai, Miyagi 980 8574, Japan 2 Department of Pathology and Oncology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Sci Rep 4:5927. 2014
    ..These results indicate that a non-mTOR pathway, critical for embryogenesis, is being regulated by tuberin, providing a link between tuberin expression and the severity of Tsc2 mutation-related pathogenesis. ..
  71. doi request reprint Inhibition of invasion by glycogen synthase kinase-3 beta inhibitors through dysregulation of actin re-organisation via down-regulation of WAVE2
    Yuki Yoshino
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Seiryo machi 4 1, Aoba ku, Sendai 980 8575, Japan
    Biochem Biophys Res Commun 464:275-80. 2015
    ..Collectively, we propose that the WAVE2-actin cytoskeleton axis is an important target of GSK-3β inhibitors in cancer cell invasion. ..
  72. ncbi request reprint [Brief description of the revised plan to promote cancer control programs in Miyagi]
    Chikashi Ishioka
    Dept of Clinical Oncology, Tohoku University, Japan
    Gan To Kagaku Ryoho 40:570-4. 2013
    ..Here, the first and revised Plan to Promote Cancer Control Programs in Miyagi was briefly described. ..
  73. ncbi request reprint [Foster Plans for Cancer Specialists selected by MEXT in Japan]
    Chikashi Ishioka
    Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Gan To Kagaku Ryoho 35:391-6. 2008
    ....
  74. ncbi request reprint FDG PET and gallium scintigraphy for diagnosis of an advanced jejunal adenocarcinoma with distant metastases
    Gengo Yamaura
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University Hospital, Sendai, Japan
    Clin Nucl Med 29:825-7. 2004
  75. ncbi request reprint PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma
    Hideaki Kato
    Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan
    J Clin Neurosci 11:37-41. 2004
    ..0012). The results indicate that the evaluation of PTEN mutation and MIB-1 LI are useful to predict dissemination and prognosis of glioblastomas...